Predicting Alzheimer's Disease Phenotypes With Aging Clocks: An Exploratory Analysis

Authors

Cindy David Sarmento[1], Gabin Drouard[1], Toni T Saari[1], Aino Aaltonen[1], Aino Heikkinen[1,2], Teemu Palviainen[1], Sanna-Kaisa Herukka[3,4], Tarja Kokkola[3], Sari Kärkkäinen[3,4], FinnGen, Aarno Palotie[1,5,6], Valtteri Julkunen[1,3,4], Heiko Runz[1], Jaakko Kaprio[1], Miina Ollikainen[1,2], Eero Vuoksimaa[1]

Affiliations

1. Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland
2. Minerva Foundation Institute for Medical Research, Helsinki, Finland
3. Institute of Clinical Medicine/Neurology, University of Eastern Finland, Kuopio, Finland
4. Department of Neurology, Neurocenter, Kuopio University Hospital, Kuopio, Finland
5. Analytic and Translational Genetics Unit, Department of Medicine, Department of Neurology and Department of Psychiatry Massachusetts General Hospital, Boston, Massachusetts, USA
6. The Stanley Center for Psychiatric Research and Program in Medical and Population Genetics, The Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA

Corresponding authors

Cindy David Sarmento - cindy.sarmento@helsinki.fi

Gabin Drouard - gabin.drouard@helsinki.fi

Abstract

Background: Due to the continuous aging of the world's population, early diagnosis of age-related diseases, such as Alzheimer's disease (AD), has become a priority and should be improved by accessible, minimally invasive, comprehensive approaches.

Methods: In this study, we explored the potential of epigenetic and proteomic aging clocks as complementary biomarkers to established cognitive tests and AD blood-based biomarkers (BBBs). Omics data were generated from blood samples of 153 cognitively unimpaired individuals, aged on average 62 years. BBBs and cognitive functioning were measured approximately nine years later. We used Generalized Estimating Equation models to investigate associations between biological aging and AD-related phenotypes, and how dementia risk factors modulate these.

Findings: Proteomic mortality-based clocks showed more significant associations with cognitive measures and BBBs than epigenetic clocks. Accelerated systemic and brain-specific proteomic aging was linked to lower cognitive functioning and higher plasma levels of neurofilament light chain (NfL). Multiple organ-specific proteomic models were positively associated with plasma NfL, indicating that changes in biological processes and cellular components in these organs, captured by these models, may be implicated in neurodegeneration and AD pathogenesis. Interaction analysis showed that negative associations of proteomic aging with cognitive scores are stronger in individuals with lower genetic liability for type II diabetes and high levels of fasting glucose.

Interpretation: In our modest-sized sample, proteomic clocks better captured variability in cognition and AD-related biomarkers than epigenetic clocks, and may have higher potential as auxiliary biomarkers of AD. Thus, our study highlights the importance of investigating proteomic aging in AD.

Funding: EH-Epi data used in the analysis is deposited in the Biobank of the Finnish Institute for Health and Welfare (https://thl.fi/en/web/thl-biobank/forresearchers). It is available to researchers after written application and following the relevant Finnish legislation.

Introduction

Due to increasingly older populations, it has been estimated that, globally, over 150 million people will be affected by dementia in 2050, the equivalent of a 166% increase in just 30 years.[1] Alzheimer's disease (AD) is the most common cause of dementia and represents a great burden to individuals, their families, and public health, as the current practice often results in late diagnosis and a long lifetime spent with severe disability.[2] Thus, early diagnosis is essential to ensure opportunities for future financial and legal planning, and for early medical interventions to delay cognitive decline.[2,3]

AD is a highly complex and multifactorial neurodegenerative disease greatly dependent on genetics and potentially modifiable risk factors,[4] with age recognized as the strongest risk factor.[5] Aging-related molecular changes are typically interconnected, leading to physiological repercussions across several organs, and consequently, to the co-occurrence of several age-related diseases.[6] In recent years, advances in multi-omics have enabled the development of aging clocks. These tools predict biological age from molecular features (*e.g.,* DNA methylation) and have successfully detected accelerated molecular aging associated with age-related diseases and dementia.[7] Although some DNA methylation-based epigenetic clocks, such as the DNAm PhenoAge and GrimAge, have shown significant associations between accelerated aging and lower cognition and other AD hallmarks,[8,9] the findings in AD literature are inconsistent, with multiple studies failing to find significant associations with AD phenotypes.[10] While epigenetic clocks currently represent the most widely used approach to assess biological aging, newly developed proteomic clocks hold great promise in AD research.[11,12] The characteristic accumulation of beta-amyloid (Aβ) and phosphorylated tau (p-tau) aggregates in individuals with AD results from disruptions in the protein homeostasis network, which should be reflected in the proteomes and thus may be detectable by proteomic clocks.[13,14] More recently, studies have introduced organ-specific proteomic clocks to evaluate the heterogeneity of organ aging and its impact on morbidity.[15–17] Overall, these have provided further evidence that molecular aging processes are interconnected, as most fast-aging organs are associated with multiple diseases.[15–17] Regarding dementia and AD, in addition to accelerated proteomic brain aging,[15,16] fast-aging immune [17] and vascular [15] systems have also been associated with a higher incidence risk.

The Alzheimer's Association workgroup's revised guidelines from 2024 highlighted a more comprehensive approach to AD risk stratification to tackle the complexity added by common co-pathologies.[3] Combining existing AD biomarkers and lifestyle and health data with

molecular biomarkers of aging, including those captured by aging clocks, could provide better insights into an individual's pathophysiology of AD before the occurrence of cognitive symptoms, which is essential to an early diagnosis. However, to our knowledge, the utility of the recently developed proteomic aging clocks in predicting early cognitive impairment, and in particular state-of-the-art AD-related plasma biomarkers, has not been evaluated in cognitively unimpaired individuals.

In this study, we leveraged an extensively phenotyped dataset of 153 individuals without a clinical diagnosis of AD to explore the utility of proteomic and epigenetic aging clocks in predicting several AD-related phenotypes. We investigated the associations of aging clocks with cognitive measures and blood-based biomarkers (BBBs), and the extent to which common dementia risk factors, namely hypertension, hypercholesterolemia, and diabetes, modulate identified associations. We hypothesized that proteomic aging clocks, particularly those that are organ-specific and relevant to organs involved in AD, may better explain variability in cognitive performance than epigenetic aging clocks.

Research in context

Evidence before this study:

On 8th July 2025, we conducted an advanced search in PubMed Central, which allows full-text searches, without any language or publication date restrictions, using the terms ((proteomic OR epigenetic) AND aging clocks AND dementia). We obtained a total of 1363 publications, with a crashing majority revolving around epigenetic data evidence. Due to the characteristic disruption in proteostasis in Alzheimer's disease (AD), plasma proteomics has great potential as an early diagnostic tool. Although there is evidence correlating systemic and brain-, immune-, and artery-specific proteomic aging clocks with increased risk of dementia, their power in predicting early cognitive impairment and AD biomarkers, in the general population, remains underexplored.

Added value of this study:

We examined associations of epigenetic and proteomic clocks with cognitive test scores and gold-standard AD-related biomarkers in cognitively unimpaired individuals, integrating also health questionnaire data to evaluate how common dementia risk factors modulate identified associations. To our knowledge, this is the first study leveraging such an extensively phenotyped sample of individuals without an AD diagnosis to evaluate the clocks' potential for early diagnosis. Our exploratory analysis suggested that proteomic aging clocks may capture variability in AD risk better than epigenetic clocks, but their performance is affected by genetic liability to diabetes.

Implications of all the available evidence:

Overall, our findings, together with prior evidence, support the potential of plasma proteomic models as auxiliary early AD diagnostic biomarkers. Moreover, our results support the benefit of applying comprehensive approaches, integrating multi-omics, established AD blood biomarkers, cognitive testing, lifestyle, and health data, in AD risk assessment, addressing the confounding effects of common co-morbidities. Further research is needed in more diverse populations to evaluate the generalizability of proteomic aging clocks. Additionally, the influence of other dementia risk factors needs to be assessed, as well as the clocks' added value in detecting the effect of medical interventions on cognitive health.

Methods

Study design and participants

The population-based older Finnish Twin Cohort (FTC) was started in 1974 and recruited all Finnish same-sex twins born before 1958, residing in Finland.[18] The baseline questionnaire had about a 90% participation rate, and follow-up data collections have included questionnaires on health-related topics and in-person study visits (Figure 1). Based on a 2011 questionnaire, twin pairs born between 1945 and 1957 and discordant for blood pressure were identified and later invited to participate in the Essential Hypertension EPIgenetics (EH-EPI) study.[19] From 2012 to 2015, the selected individuals (n=447) visited the clinic, where blood samples were collected. From these blood samples, multi-omics data were generated, including the epigenomic and proteomic data used in the present study, and genetic analyses were performed, including computation of polygenic risk scores (PRS) of dementia-related traits. Weight and height were also measured. In 2023, these individuals were invited to participate in the TWINGEN study.[20]

In TWINGEN, exclusion criteria were diagnosis of AD or any other neurological or psychiatric disorder affecting cognition, based on health registry data and confirmation via telephone interview.[20] Individuals were included in the study independently of their co-twin's eligibility. The protocol applied to all selected individuals comprised health questionnaires, telephone and computer-based cognitive testing, blood pressure measures, and blood draws. These new blood samples were used for the quantification of plasma biomarkers of AD as outcome traits.



Figure 1. Flow chart of sample selection.

Outcomes: cognition and AD-related biomarkers

Cognitive measures from the year 2023 consisted of scores for computer- and telephone-administered cognitive tests, Reaction Time (RT), and AD-related BBBs phosphorylated tau 217 (p-tau217), glial fibrillary acidic protein (GFAP), and neurofilament light chain (NfL) (Figure 2; Supplementary Table S1). Cognitive tests included a re-modified version of the Telephone Interview for Cognitive Status (TICS-m3)[21] and the web-based tool cCOG, which have been validated for early detection of cognitive impairment and AD against the gold standard, in-person administered, CERAD-nb.[21] RT measured in a cCOG subtest was also included as a separate measure.

Among the BBBs considered in this study, p-tau217 corresponds to an early-changing Core 1 biomarker, as defined by the Alzheimer's Association workgroup in 2024.[3] It is specific to AD neuropathological changes, reflecting both Aβ and tau pathologies. Abnormal levels of p-tau217 in plasma may be found in cognitively unimpaired individuals and are associated with older age in population-level analysis.[22] NfL and GFAP are non-core biomarkers, indicative of neurodegeneration and inflammation/immune processes, respectively, and are non-specific for AD.[3] BBBs were quantified from TWINGEN blood samples using Simoa HD-X Analyzer (Quanterix, Billerica, Massachusetts, USA).[20]

Predictors: epigenomic and proteomic aging clocks

DNA methylation and proteomic data were obtained from EH-EPI blood samples,[23] eight to ten years before the TWINGEN study, and used to compute epigenetic and proteomic age estimates, respectively, which constituted the predictors in our analyses. DNA methylation (Illumina Infinium Human Methylation 450K Beadchip) and proteomic data (Olink Explore 3072) were processed for quality control as described by Drouard *et al.*[24]

Epigenetic age acceleration estimates were computed as in Drouard *et al.*[24] by regressing chronological age onto the following epigenetic clock estimates: Horvath,[25] Hannum,[26] PhenoAge,[8] GrimAge,[27] GrimAge2,[28] and DunedinPACE.[29] Proteomic clocks included the Proteomic Aging Clock (PAC)[11] and Healthspan Proteomic Score (HPS)[12] and were estimated according to the developers' instructions. These were also utilized in a previous investigation,[12] which reported correlations with chronological age and epigenetic clocks. In contrast with other clocks, which predict chronological age or mortality risk, HPS informs about the likelihood of remaining healthy, *i.e.*, not developing any disease included in the healthspan definition (cancer, diabetes, heart failure, myocardial infarction, stroke, chronic obstructive pulmonary disease, and dementia) nor dying within 10 years from the baseline.

Here, we used the estimate $1 - HPS$ to depict morbidity/mortality hazard, in conformity with the other clocks.

We also employed recently developed second-generation systemic and organ-specific proteomic aging clocks, which are trained on mortality data instead of chronological age.[16] These have been reported to correlate with chronological age and outperform other clocks in predicting mortality and the risk of organ-specific diseases.[16] We selected organ-specific clocks relevant to organs or systems directly involved in AD pathology (brain) or potentially involved in AD, considering previously reported associations with different dementia types (artery, heart,[15] immune system, and intestine[17]) and relation to major AD risk factors (pancreas – diabetes). The kidney-specific clock was also included due to evidence that accelerated kidney aging has effects across multiple organs and is associated with multiple age-related diseases.[17] Additionally, over-representation analysis (ORA) of gene sets from each organ clock (see Supplementary Materials for extended methods), motivated the inclusion of the adipose- and liver-specific clocks due to significant enrichment in gene ontology (GO) terms and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways relative to glucose transport and metabolism, type II diabetes *mellitus*, and acute inflammatory responses.

Possible interactors: dementia risk factors

We retrieved information on self-reported diabetes status (yes/no), glucose and cholesterol levels (elevated/normal) from available TWINGEN questionnaires. We also gathered measures of blood pressure taken in the context of the TWINGEN study, and self-reported values when measures were not available. Additionally, we considered polygenic risk scores (PRS) for AD, EA, type II diabetes (T2D), fasting glucose (fg) and insulin (fi), coronary artery disease (CAD), low-density lipoprotein (LDL), and for systolic (SBP) and diastolic blood pressure (DBP). These variables were tested as possible interactors (Supplementary Table S1) in cognition-clock associations.

Statistical analyses

All statistical analyses were performed in R version 4.4.2. [30] and can be summarized into three major steps (Figure 2):

(1) Association analysis between cognition (cognitive tests' scores and BBBs) and biological age (epigenomic and proteomic aging clocks).
(2) Association analysis between cognition and possible interactors (diabetes status, blood pressure levels, *etc.*).

(3) Interaction analysis for each interactor and aging clock with a significant association with cognition.

Generalized estimating equation (GEE) models were used for each step to account for the correlations within the data due to twins' familial relatedness. Sex assigned at birth obtained from a population registry, chronological age at first blood sampling for omics data generation (EH-EPI study), and time in years between blood sampling and cognitive testing (DiffAge; TWINGEN study) were added as covariates in all models. Prior to association and interaction analyses, all biological age estimates were normalized using rank-based inverse-normal transformation to unify the scales and correct distributional skewness. In addition, continuous outcomes and predictors were scaled. We reported T-values, 95% confidence intervals (CI), and *p*-values adjusted for multiple testing with the Benjamini-Hochberg (BH) method in step (1), and nominal *p*-values in the following steps (2) and (3).

We performed interaction analyses to test the potential effect of the genetic predisposition for AD and educational attainment (EA), as well as having diabetes, hypertension, and hypercholesterolemia (common risk factors of dementia), in modulating associations between cognition and aging clocks. Possible interactors considered in the analyses were described in the previous section and summarized in Supplementary Table S1. To correct for population structure, PRSs were regressed on the first ten genetic principal components, and then scaled in subsequent analyses. To explore significant interaction effects, we stratified individuals into two PRS groups: low risk (below average) and high risk (above average). Then, we plotted biological age estimates against cognition estimates, fitting separate regression lines for each stratum.



Figure 2. Analytical approach and variables. Abbreviations: GCS – global cognitive score for the cCOG test.

Role of the funding source

The funding sources didn't contribute to study design, data collection, analysis, interpretation, or writing of the report. Submission of the present manuscript for publication required review and approval by the FinnGen Steering Committee.

Results

In this study, we investigated a total of 153 individuals with an average age at blood sampling for omics data generation (EH-EPI) of approximately 62 years. Cognition was measured (TWINGEN) on average 9 years later (Table 1).

In Figure 3 (panel 1), we reported the associations between cognition (cognitive test scores and BBBs) and aging clocks. Given the status of AD as an age-related disease, we expected that accelerated aging detected by any of the clocks tested (higher estimates) could associate with lower cognitive functioning evaluated by cCOG and TICS-m3 (negative associations), higher RT, and increased levels of BBBs (positive associations).

Among all clocks, only DunedinPACE had a significant association with plasma GFAP levels; unexpectedly, the decelerated pace of aging was associated with higher levels of the inflammation biomarker. Moreover, this was the only epigenetic clock associated with a BBB or cognitive test measure.

Most significant associations detected involved proteomic clocks. As expected, accelerated brain aging was associated with lower cognitive performance (in both TICS-m3 and cCOG) and higher plasma NfL levels. Plasma NfL showed the highest number of significant associations with biological aging, in particular positive associations with multiple organ-specific and system-wide proteomic clocks (Figure 3, panel 1). None of the clocks were significantly associated with either p-tau217 or RT.

For all cognitive and biomarker measures that were significantly associated with an aging clock (GCS, TICS-m3 score, GFAP, and NfL), we further tested for possible interactors – indicators of diseases, or genetic liability to them, that are AD risk factors – and investigated if these modulated the cognition-clock associations. First, we found significant associations between GCS and glucose levels, EA-PRS and fg-PRS. Additionally, GFAP was significantly associated with glucose levels, TICS-m3 score with T2D-PRS, and NfL with LDL-PRS (Figure 3, panel 2). Interaction analysis revealed that only two interactions were nominally significant, suggesting that T2D-PRS may modulate the association between brain aging and TICS-m3 scores, and that fg-PRS may modulate the association between $1 - HPS$ and GCS. More specifically, for individuals with higher PRSs, the associations between these aging clocks and cognition scores were weaker than in those with lower PRSs (Figure 3, panel 3).

Table 1. General characteristics of the study sample. Age, weight, height, and BMI values correspond to values at the time of blood sampling in the EH-EPI study. DiffAge corresponds to the time gap between blood sampling and cognitive testing in the TWINGEN study. Abbreviations: MZ – monozygotic; DZ – dizygotic; BMI – body mass index; SD – standard deviation.

	Total	**Female**	**Male**
N	153	105 (69%)	48 (31%)
Zygosity – MZ / DZ (N, %)	92 (60%) / 61 (40%)	67 / 38	25 / 23
Full pairs – MZ / DZ	35 / 18	27 / 12	8 / 6
Age – mean [SD]	61·84 [3·59]	61·91 [3·61]	61·71 [3·58]
DiffAge – mean [SD]	9·25 [0·70]	9·24 [0·68]	9·26 [0·75]
Weight – mean [SD] kg	73·53 [14·01]	69·36 [11·78]	82·66 [14·29]
Height – mean [SD] cm	166·45 [8·42]	162·13 [5·22]	175·90 [6·01]
BMI – mean [SD]	26·47 [4·31]	26·40 [4·52]	26·63 [3·87]



Figure 3. Association and interaction analyses' results. (1) Associations of cognition measures and AD blood biomarkers with epigenetic and proteomic clocks. (2) Associations of cognition and AD blood biomarkers with nine PRSs, glucose, cholesterol, blood pressure measures, and diabetes status. (3) Effect of type II diabetes and fasting glucose PRSs in

cognition-biological age associations. Biological aging clocks are scaled. Statistically significant associations, defined as adjusted *p*-values below 0.05 in Panel 1 or nominal *p*-values below 0.05 in Panels 2 and 3, are highlighted in red.

Discussion

Our study leverages a small but extensively phenotyped sample of cognitively unimpaired individuals to unveil potential associations between biological aging and state-of-the-art markers of cognitive functioning and AD, as well as possible modifiers of these associations.

Despite the small sample size, we were able to retrieve significant associations that persist after multiple testing correction. The results suggested several significant associations of accelerated systemic and brain-specific proteomic aging with lower cognitive performance. Additionally, multiple proteomic clocks also revealed significant associations between accelerated aging and higher plasma levels of NfL. These observations support the definition of AD as an age-related disease and the potential of plasma proteomics as auxiliary biomarkers of early cognitive decline and neurodegeneration.

The significant associations of NfL with the artery, heart, and immune system aging clocks, in addition to the brain and systemic proteomic clocks, may have multiple explanations. First, NfL is a non-AD-specific neurodegeneration biomarker occurring in abnormal levels in multiple diseases that imply or lead to neuronal loss.[3] Therefore, individuals with multiple fast-aging organs may be more likely to show increased levels of NfL. When we consider also nominally significant *p*-values (Supplementary Figure S1), we additionally retrieve associations with the adipose, intestine, and liver clocks. Certain proteins used to build these organ-specific clocks may be involved in processes or cellular components related to the nervous system or AD risk factors, driving AD pathogenesis and the associations with NfL. For example, GO and KEGG's pathway enrichment analysis highlighted aggrecan protein (*ACAN*) from the artery clock as a major component of perineuronal nets (PNNs; Supplementary Figure S3). Prior reports have suggested that PNNs have protective functions on neurons, more specifically, against tau pathology: aggrecan seems to bind to exogenous tau aggregates, trapping them in the extracellular space and preventing their internalization (see [31] for a review). Thus, changes in *ACAN* gene expression alter PNN composition, disrupting its integrity and protective role.[31] These changes may be captured by the artery clock studied here, pointing to its potential in detecting AD-related pathology.

Furthermore, proteins encoded by *BMP10* (bone morphogenetic protein 10), *MYL4* (myosin light chain 4), *TNNI3* (troponin I3), and *NPPB* (natriuretic peptide B), comprised in the heart-specific model, are involved in pathways regulating blood circulation and blood pressure (Supplementary Figure S5). Additionally, proteins from the adipose clock indicated enrichment in KEGG's type II diabetes *mellitus* pathway. More concretely, adiponectin (coding gene: *ADIPOQ*) and leptin (*LEP*) are concerned with multiple GOs related to glucose

metabolism and transport (Supplementary Figure S2). This prompted us to perform an interaction analysis to clarify the influence of cardiovascular diseases and diabetes on the detected cognition-clock associations. Our findings indicated stronger negative associations between cognition and aging in individuals with lower genetic liability for type II diabetes and for high levels of fasting glucose. These results were consistent with a previous study that reported stronger associations between BBBs of AD, particularly p-tau217, and the levels of brain Aβ in those without diabetes or cardiovascular disorders.[32] Altogether, these findings indicate that diabetes status may significantly affect the performance of proteomic clocks in predicting decline in cognitive functioning, which warrants further studies to validate.

In contrast with proteomic clocks, only one epigenetic clock, DunedinPACE, showed a significant association, particularly with the non-AD-specific plasma biomarker of inflammation, GFAP. Notably, this was the only clock, among all tested, with a significant association with this biomarker. Since DunedinPACE was developed based on longitudinal epigenetic data, it is fundamentally distinct from the other clocks used here. It estimates not exactly biological aging, but the pace at which aging and system decline occur.[29] Our results suggest that this methodology might capture aspects of the relationship between biological aging and changes in biomarkers of AD that other methodologies don't in modest-sized samples. Unexpectedly, higher levels of plasma GFAP were associated with a slower pace of aging, approximately nine years prior. One reason for this may be that individuals who live long enough to develop AD are expected to have a slower systemic aging rate, while individuals with faster aging rates are more likely to die of other causes before the start of cognitive decline and AD onset, as suggested by Goeminne *et al*.[16]

Overall, considering the number of associations detected with proteomic clocks in comparison to epigenetic clocks, it appears that the former may better capture variability in cognition and AD-related biomarkers than the latter in modest-sized study samples like ours. Yet, it is worth mentioning the imbalance in the number of epigenetic and proteomic clocks studied here – six and 12, respectively – and the differences in models and data types used to develop them. Our analyses included both 1st-generation clocks trained on chronological age (Horvath and Hannum) and 2nd-generation clocks trained on either mortality or morbidity data. From multiple previous reports, it was expected that both epigenetic and proteomic mortality-based models would perform better than 1st-generation ones in predicting the risk of age-related diseases and mortality (*eg,* [8,16,27]). In the end, the clocks' performance in this context might depend not only on the omic layer from which they are derived but also on their methodological foundation.

We acknowledge the limitations imposed on the generalizability of our results by the lack of racial and ethnic diversity in our dataset, which consisted exclusively of Finnish individuals with a very homogeneous white European background. However, regarding educational background, our study sample provided more diversity than most, comprising individuals with poorer educational attainment as well as highly educated individuals. In addition, we recognize that, as the small sample size greatly limits the statistical power of our analyses, our study remains exploratory. However, we would like to highlight the unique richness in data types in this sample, which included proteomic, epigenetic, genetic, cognitive testing, health registry, and longitudinal questionnaire data.

In conclusion, in the presented context of a small sample of cognitively unimpaired individuals, our findings suggest the superior performance of proteomic mortality-based aging clocks in comparison to epigenetic clocks and their potential as supplementary biomarkers of AD. We also showed that proteomic aging clocks may differentially capture variability in AD-related outcomes among individuals at high genetic risk for diabetes. Further research efforts to investigate the effect of other co-morbidities and risk factors, particularly those involving immune and inflammation processes, may help clarify the added value of these aging clocks in the early diagnosis of AD. Longitudinal studies may also be beneficial to understand how medical interventions on modifiable risk factors may modulate biological aging and cognitive functioning.

Author contributions

Conceptualization: CDS, GD, EV

Methodology: CDS, GD

Formal analysis: CDS

Investigation: CDS, GD, SH, TK, SJ, EV

Resources: VJ, JK, MO, EV, FinnGen

Data curation: CDS, GD, AH, TTS, AA

Writing – Original Draft: CDS, GD, EV

Visualization: CDS

Supervision: GD, EV

Funding acquisition: EV, FinnGen

All authors reviewed and revised the original draft of the manuscript and approved the final version.

Declaration of interests

A.P. is the Chief Scientific Officer of the FinnGen project, which is funded by 14 industry partners: AbbVie Inc., AstraZeneca UK Ltd, Biogen MA Inc., Bristol Myers Squibb (and Celgene Corporation & Celgene International II Sàrl), Genentech Inc., Merck Sharp & Dohme LCC, Pfizer Inc., GlaxoSmithKline Intellectual Property Development Ltd., Sanofi US Services Inc., Maze Therapeutics Inc., Janssen Biotech Inc, Novartis Pharma AG, Boehringer Ingelheim International GmbH, and Bayer.

H.R. is currently employed at Insitro Inc. He is a former employee and holds stock at Merck & Co and Biogen Inc.

The authors declare no other competing financial or non-financial interests.

Data sharing

TWINGEN data are stored at the THL Biobank for those participants who gave consent for transferring their data to the biobank. Data are available to qualified applicants from academia and companies. For further details on the application process, see: https://thl.fi/en/research-and-development/thl-biobank/for-researchers/application-process.

Ethics and consent statement

The TWINGEN protocol received ethical approval by the Coordinating Ethics Committee of the Hospital District of Helsinki and Uusimaa (HUS) (number 16831/2022), and the research

plan was approved by THL Biobank (THLBB2022_83). All participants gave written informed consent before their participation and had the option to withdraw from the study at any point.

Acknowledgments

We thank all participants of the older Finnish Twin Cohort study who participated in the TWINGEN study, recruited through THL Biobank (study number THLBB2022_83).

We want to acknowledge the participants and investigators of the FinnGen project, which funded the TWINGEN study. The FinnGen project is funded by two grants from Business Finland (HUS 4685/31/2016 and UH 4386/31/2016) and the following industry partners: AbbVie Inc., AstraZeneca UK Ltd, Biogen MA Inc., Bristol Myers Squibb Inc. (and Celgene Corporation & Celgene International II Sàrl), Genentech Inc., Merck Sharp & Dohme LCC, Pfizer Inc., GlaxoSmithKline Intellectual Property Development Ltd., Sanofi US Services Inc., Maze Therapeutics Inc., Johnson&Johnson Innovative Medicine Inc., Novartis AG, Boehringer Ingelheim International GmbH and Bayer AG. Following biobanks are acknowledged for delivering biobank samples to FinnGen: Auria Biobank (www.auria.fi/biopankki), THL Biobank (www.thl.fi/biobank), Helsinki Biobank (www.helsinginbiopankki.fi), Biobank Borealis of Northern Finland (https://www.ppshp.fi/Tutkimus-ja-opetus/Biopankki/Pages/Biobank-Borealis-briefly-in-English.aspx), Finnish Clinical Biobank Tampere (www.tays.fi/en-US/Research_and_development/Finnish_Clinical_Biobank_Tampere), Biobank of Eastern Finland (www.ita-suomenbiopankki.fi/en), Central Finland Biobank (www.ksshp.fi/fi-FI/Potilaalle/Biopankki), Finnish Red Cross Blood Service Biobank (www.veripalvelu.fi/verenluovutus/biopankkitoiminta), Terveystalo Biobank (www.terveystalo.com/fi/Yritystietoa/Terveystalo-Biopankki/Biopankki/) and Arctic Biobank (https://www.oulu.fi/en/university/faculties-and-units/faculty-medicine/northern-finland-birth-cohorts-and-arctic-biobank). All Finnish Biobanks are members of BBMRI.fi infrastructure (https://www.bbmri-eric.eu/national-nodes/finland/). Finnish Biobank Cooperative – FINBB (https://finbb.fi/) is the coordinator of BBMRI-ERIC operations in Finland. The Finnish biobank data can be accessed through the Fingenious® services (https://site.fingenious.fi/en/) managed by FINBB.

E.V. was supported by the Sigrid Jusélius Foundation.

Figures were created in https://BioRender.com.

References

1 GBD 2019 Dementia Forecasting Collaborators. Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study 2019. *Lancet Public Health* 2022; **7**: e105–25.

2 2024 Alzheimer's disease facts and figures. *Alzheimers Dement* 2024; **20**: 3708–821.

3 Jack Jr. CR, Andrews JS, Beach TG, *et al.* Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup. *Alzheimers Dement* 2024; **20**: 5143–69.

4 Livingston G, Huntley J, Liu KY, *et al.* Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission. *The Lancet* 2024; **404**: 572–628.

5 Zheng Q, Wang X. Alzheimer's disease: insights into pathology, molecular mechanisms, and therapy. *Protein Cell* 2025; **16**: 83–120.

6 Fraser HC, Kuan V, Johnen R, *et al.* Biological mechanisms of aging predict age-related disease co-occurrence in patients. *Aging Cell* 2022; **21**: e13524.

7 Rutledge J, Oh H, Wyss-Coray T. Measuring biological age using omics data. *Nat Rev Genet* 2022; **23**: 715–27.

8 Levine ME, Lu AT, Quach A, *et al.* An epigenetic biomarker of aging for lifespan and healthspan. *Aging* 2018; **10**: 573–91.

9 Hillary RF, Stevenson AJ, Cox SR, *et al.* An epigenetic predictor of death captures multi-modal measures of brain health. *Mol Psychiatry* 2021; **26**: 3806–16.

10 Milicic L, Porter T, Vacher M, Laws SM. Utility of DNA Methylation as a Biomarker in Aging and Alzheimer's Disease. *J Alzheimers Dis Rep* 2023; **7**: 475–503.

11 Kuo C-L, Chen Z, Liu P, *et al.* Proteomic aging clock (PAC) predicts age-related outcomes in middle-aged and older adults. *Aging Cell* 2024; **23**: e14195.

12 Kuo C-L, Liu P, Drouard G, *et al.* A proteomic signature of healthspan. *Proc Natl Acad Sci* 2025; **122**: e2414086122.

13 López-Otín C, Blasco MA, Partridge L, Serrano M, Kroemer G. Hallmarks of aging: An expanding universe. *Cell* 2023; **186**: 243–78.

14 Labbadia J, Morimoto RI. The Biology of Proteostasis in Aging and Disease. *Annu Rev Biochem* 2015; **84**: 435–64.

15 Oh HS-H, Rutledge J, Nachun D, *et al.* Organ aging signatures in the plasma proteome track health and disease. *Nature* 2023; **624**: 164–72.

16 Goeminne LJE, Vladimirova A, Eames A, *et al.* Plasma protein-based organ-specific aging and mortality models unveil diseases as accelerated aging of organismal systems. *Cell Metab* 2025; **37**: 205-222.e6.

17 Kivimäki M, Frank P, Pentti J, *et al.* Proteomic organ-specific ageing signatures and 20-year risk of age-related diseases: the Whitehall II observational cohort study. *Lancet*

Digit Health 2025; **7**: e195–204.

18 Kaprio J, Bollepalli S, Buchwald J, *et al.* The Older Finnish Twin Cohort — 45 Years of Follow-up. *Twin Res Hum Genet* 2019; **22**: 240–54.

19 Huang Y, Ollikainen M, Muniandy M, *et al.* Identification, Heritability, and Relation With Gene Expression of Novel DNA Methylation Loci for Blood Pressure. *Hypertension* 2020; **76**: 195–205.

20 Vuoksimaa E, Saari TT, Aaltonen A, *et al.* TWINGEN: protocol for an observational clinical biobank recall and biomarker cohort study to identify Finnish individuals with high risk of Alzheimer's disease. *BMJ Open* 2024; **14**: e081947.

21 Aaltonen A, Saari T, Urjansson M, *et al.* Telephone- and computer-administered instruments in detection of cognitive impairment. 2024; published online Nov 13. DOI:10.31234/osf.io/5wy6c.

22 Saari TT, Palviainen T, Hiltunen M, *et al.* Cross-sectional study of plasma phosphorylated tau 217 in persons without dementia. *Alzheimers Dement Diagn Assess Dis Monit* 2025; **17**: e70107.

23 Drouard G, Ollikainen M, Mykkänen J, *et al.* Multi-Omics Integration in a Twin Cohort and Predictive Modeling of Blood Pressure Values. *OMICS J Integr Biol* 2022; **26**: 130–41.

24 Drouard G, Suhonen S, Heikkinen A, Wang Z, Kaprio J, Ollikainen M. Multi-Omic Associations of Epigenetic Age Acceleration Are Heterogeneously Shaped by Genetic and Environmental Influences. *Aging Cell* 2025; **n/a**: e70088.

25 Horvath S. DNA methylation age of human tissues and cell types. *Genome Biol* 2013; **14**. DOI:10.1186/gb-2013-14-10-r115.

26 Hannum G, Guinney J, Zhao L, *et al.* Genome-wide Methylation Profiles Reveal Quantitative Views of Human Aging Rates. *Mol Cell* 2013; **49**: 359–67.

27 Lu AT, Quach A, Wilson JG, *et al.* DNA methylation GrimAge strongly predicts lifespan and healthspan. *Aging* 2019; **11**: 303–27.

28 Lu AT, Binder AM, Zhang J, *et al.* DNA methylation GrimAge version 2. *Aging* 2022; **14**: 9484–549.

29 Belsky DW, Caspi A, Corcoran DL, *et al.* DunedinPACE, a DNA methylation biomarker of the pace of aging. *eLife* 2022; **11**: e73420.

30 R Core Team. R: A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing, 2024 https://www.R-project.org/.

31 Zhu K, Fu Y, Zhao Y, Niu B, Lu H. Perineuronal nets: Role in normal brain physiology and aging, and pathology of various diseases. *Ageing Res Rev* 2025; **108**: 102756.

32 Olvera-Rojas M, Sewell KR, Karikari TK, *et al.* Influence of medical conditions on the diagnostic accuracy of plasma p-tau217 and p-tau217/Aβ42. *Alzheimers Dement* 2024; **21**: e14430.